BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
241 hedge funds and large institutions have $5.17B invested in bluebird bio in 2017 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 95 increasing their positions, 66 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
22% more capital invested
Capital invested by funds: $4.24B → $5.17B (+$938M)
15% more funds holding
Funds holding: 210 → 241 (+31)
0.3% less ownership
Funds ownership: 8.81% → 8.51% (-0.3%)
Holders
241
Holding in Top 10
4
Calls
$109M
Puts
$49M
Top Buyers
| 1 | +$63.1M | |
| 2 | +$61.7M | |
| 3 | +$51.8M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$28.9M |
Top Sellers
| 1 | -$50.4M | |
| 2 | -$25.4M | |
| 3 | -$21.1M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$16.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$16.3M |